dr. burgess on the synergy between abiraterone and adt in prostate cancer
Published 5 years ago • 231 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:26
dr. burgess on key data in metastatic castration-sensitive prostate cancer
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
1:05
dr. burgess on immunotherapy in prostate cancer
-
1:26
dr. oh discusses choosing abiraterone in prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
1:12
dr. dreicer on the current role of abiraterone and enzalutamide in prostate cancer
-
1:38
5-year follow up of short-course abiraterone and adt for high-risk prostate cancer
-
12:11
triggers to initiate androgen-deprivation therapy (adt) in prostate cancer
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
1:32
dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
1:25
dr. mohler on overuse of adt in prostate cancer and nccn guidelines
-
1:18
dr. aggarwal on the future of adt for patients with prostate cancer
-
2:06
dr. chi on androgen deprivation therapy for high-risk metastatic hormone-naive prostate cancer
-
8:19
prostate cancer: adverse event management in adt
-
7:58
abiraterone and chemotherapy in crpc
-
1:24
dr. tward on abbreviated course adt for prostate cancer